|Articles|January 8, 2020

Catalent Unveils New European Product Launch Site

Author(s)Catalent

Catalent’s site in Anagni, Italy offers extensive capabilities in aseptic liquid and powder filling, as well as comprehensive packaging solutions to support product launches for oral solids, sterile, and biologics products.

Catalent’s new 28,000 square-meter (305,000 square-feet) facility in Anagni, Italy has a demonstrated track record in technical transfers and successful commercial product launches and will enhance its European biologics business by providing customers with access to:

- Liquid and powder filling of vials for sterile and biologic products

- Secondary packaging for sterile and biologic products, including labelling and cartoning

- Automated inspection, packaging, and warehousing

- Serialisation

- World-class expertise in global product launches

The state-of-the-art facility for late phase tech transfers and commercial launches complements Catalent Biologics' existing facilities in Brussels, Belgium, providing process development, filling of syringes for sterile and biologic products, and device assembly and packaging.

The site will also offer oral solid dose commercial packaging capabilities and work alongside facilities in Schorndorf, Germany and Nottingham, United Kingdom to accelerate late-phase tech transfers and commercial product launches.

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.